Navigation Links
Hospira Joins the Generic Pharmaceutical Association
Date:2/23/2012

LAKE FOREST, Ill., Feb. 23, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today that it has joined the Generic Pharmaceutical Association (GPhA). Hospira is dedicated to Advancing Wellness, a goal that matches well with the GPhA's core purpose of bringing affordable medications to patients who need them.

"Hospira is pleased to announce our membership in the GPhA today," said Thomas Moore, president, U.S., Hospira. "We commend the leadership shown by GPhA President Ralph Neas and the excellent staff he has assembled. GPhA is a strong industry trade association that will continue to work tirelessly to bring the safest, high-quality, lower-cost generic drugs to patients and families who need them, and Hospira looks forward to working with the association on the many pressing issues facing our industry."

"We are pleased to welcome Hospira to GPhA, and we look forward to their joining in the Association's mission to improve the lives of consumers by providing timely access to affordable pharmaceuticals," said Ralph G. Neas, President and CEO of GPhA. "Hospira's products, like those of all our members, have enabled millions of Americans to obtain affordable treatments for critical conditions. Their input and participation will be a valuable asset for GPhA as we move into this new and exciting time for our industry."

As the leading provider of generic injectables in the United States with the broadest and deepest portfolio of low-cost, safe and effective products, Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. Therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

About GPhA

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 78 percent of the prescriptions dispensed in the United States but consume just 25 percent of the total drug spending. Additional information is available at gphaonline.org.

About Hospira

Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Works With FDA to Help Avert Methotrexate Shortage; Shipping One Months Supply of New Product Immediately and on Track to Ensure Sustainable Supply
2. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
3. Hospira to Host Conference Call for Fourth-Quarter 2011 Results and 2012 Projections
4. Hospira to Present at the J.P. Morgan 30th Annual Healthcare Conference Jan. 10, 2012
5. Hospira Reports Third-Quarter 2011 Results
6. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
7. Hospira to Host Conference Call for Third-Quarter 2011 Results
8. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
9. Hospira to Host 2011 Investor Day
10. Hospira to Present at the Morgan Stanley Global Healthcare Conference
11. Hospira Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies Corp. ... continues to develop collagenase based-therapies with a first ... marketed as XIAFLEX ®  in the U.S. and ... present a corporate overview at the upcoming 16 ... April 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... -- Today, CVS Health officials (NYSE: CVS ) ... Public Health Director Gerd Clabaugh and Office of ... the availability of the opioid overdose-reversal medicine naloxone without a ... has established a standing order with physicians in ... to the medication in the state.   "Naloxone ...
(Date:3/29/2017)... -- The Global Health Innovative Technology Fund (GHIT Fund), ... infectious diseases around the globe, today announced 11 ... deliver a range of new innovative therapies for ... This latest round of targeted support includes funding ... pediatric formulation of a drug considered the gold ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, ... school and college students who have participated in the program every summer. The ... now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
(Date:3/29/2017)... ... , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is ... or without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. ... patients receive early treatment, they may achieve straight teeth with less treatment in their ...
(Date:3/29/2017)... ... , ... Curio Wellness , a premium medical cannabis brand and trusted ... management team with prominent executives from both inside and outside the cannabis industry. ... Ted Dumbauld , who has more than twenty years of business leadership and investment ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
Breaking Medicine News(10 mins):